Primary Site >> Pancreatic Cancer
Gene >> SLC5A8
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
|
Ref: Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. PMID: 10606909 |
Ref: Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. PMID: 18437076 Ref: Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. PMID: 18575732 |
Ref: Matrine inhibits proliferation and induces apoptosis of pancreatic cancer cells in vitro and in vivo. PMID: 20930385 |
Ref: Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. PMID: 21714853 |
Ref: SLC5A8 nuclear translocation and loss of expression are associated with poor outcome in pancreatic ductal adenocarcinoma. PMID: 22450368 |
Ref: Antiangiogenic effects of oxymatrine on pancreatic cancer by inhibition of the NF-kappaB-mediated VEGF signaling pathway. PMID: 23754270 |
Ref: Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. PMID: 24947606 |
Ref: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic Cancer. PMID: 27127137 Ref: Insulin and SGK1 reduce the function of Na+/monocarboxylate transporter 1 (SMCT1/SLC5A8). PMID: 27488665 |
Ref: Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. PMID: 28697053 |
Ref: Matrine suppresses KRAS-driven pancreatic cancer growth by inhibiting autophagy-mediated energy metabolism. PMID: 29791786 |